Alfatide II | ligand |18F-Alfatide II | PET/CT | Breast Cancer

Alfatide II
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125677

CAS#: N/A

Description: Alfatide II is ligand for making 18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study. 18F-alfatide II has been proven to have excellent clinical translational potential.

Chemical Structure

Alfatide II

CAS# N/A

Instruction

Theoretical Analysis

MedKoo Cat#: 125677
Name: Alfatide II
CAS#: N/A
Chemical Formula: C87H128N24O28S
Exact Mass: 1,988.91
Molecular Weight: 1,990.180
Elemental Analysis: C, 52.51; H, 6.48; N, 16.89; O, 22.51; S, 1.61

Price and Availability

Size	Price	Availability
10mg	USD 1250	2 Weeks
50mg	USD 2050	2 Weeks
100mg	USD 3850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Alfatide II; Alfatide-II; AlfatideII

IUPAC/Chemical Name: 2,2',2''-(2-(4-(3-(13-((4-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)carbamoyl)-21-((2S,5S,11S,14R)-11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)-11,16-dioxo-3,6,9-trioxa-12,17-diazahenicosyl)thioureido)benzyl)-1,4,7-triazonane-1,4,7-triyl)triacetic acid

InChi Key: YNIMRGCHOCEKOJ-PDHQBNHTSA-N

InChi Code: InChI=1S/C87H128N24O28S/c88-85(89)94-27-5-9-58-77(129)97-44-68(115)101-65(42-71(118)119)83(135)107-63(40-52-13-19-56(112)20-14-52)81(133)105-60(79(131)103-58)7-1-3-25-92-67(114)24-23-62(100-70(117)50-139-38-37-138-36-35-137-34-29-96-87(140)99-54-17-11-51(12-18-54)39-55-46-110(48-74(124)125)31-30-109(47-73(122)123)32-33-111(55)49-75(126)127)76(128)93-26-4-2-8-61-80(132)104-59(10-6-28-95-86(90)91)78(130)98-45-69(116)102-66(43-72(120)121)84(136)108-64(82(134)106-61)41-53-15-21-57(113)22-16-53/h11-22,55,58-66,112-113H,1-10,23-50H2,(H,92,114)(H,93,128)(H,97,129)(H,98,130)(H,100,117)(H,101,115)(H,102,116)(H,103,131)(H,104,132)(H,105,133)(H,106,134)(H,107,135)(H,108,136)(H,118,119)(H,120,121)(H,122,123)(H,124,125)(H,126,127)(H4,88,89,94)(H4,90,91,95)(H2,96,99,140)/t55?,58-,59-,60-,61-,62?,63+,64+,65-,66-/m0/s1

SMILES Code: O=C(NCCCC[C@H]1C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC2=CC=C(O)C=C2)C(N1)=O)=O)=O)=O)=O)C(NC(COCCOCCOCCNC(NC3=CC=C(CC4CN(CC(O)=O)CCN(CC(O)=O)CCN4CC(O)=O)C=C3)=S)=O)CCC(NCCCC[C@H]5C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC6=CC=C(O)C=C6)C(N5)=O)=O)=O)=O)=O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,990.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Wu J, Wang S, Zhang X, Teng Z, Wang J, Yung BC, Niu G, Zhu H, Lu G, Chen X.
¹⁸F-Alfatide II PET/CT for Identification of Breast Cancer: A
Preliminary Clinical Study. J Nucl Med. 2018 Dec;59(12):1809-1816. doi:
10.2967/jnumed.118.208637. Epub 2018 Apr 26. PMID: 29700127; PMCID: PMC6910641.

2: Wu J, Tian J, Zhang Y, Ji H, Sun J, Wang X, Sun C, Wang L, Teng Z, Lu G, Zhu
H, Chen X. ¹⁸F-Alfatide II for the evaluation of axillary lymph nodes
in breast cancer patients: comparison with ¹⁸F-FDG. Eur J Nucl Med
Mol Imaging. 2022 Jul;49(8):2869-2876. doi: 10.1007/s00259-021-05333-z. Epub
2022 Feb 9. PMID: 35138445.

3: Yu C, Pan D, Mi B, Xu Y, Lang L, Niu G, Yang M, Wan W, Chen X. (18)F-Alfatide
II PET/CT in healthy human volunteers and patients with brain metastases. Eur J
Nucl Med Mol Imaging. 2015 Dec;42(13):2021-8. doi: 10.1007/s00259-015-3118-2.
Epub 2015 Jul 1. PMID: 26121930; PMCID: PMC4626365.

4: Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X. Pilot Prospective Evaluation
of (18)F-Alfatide II for Detection of Skeletal Metastases. Theranostics. 2015
Jul 12;5(10):1115-21. doi: 10.7150/thno.12938. PMID: 26199649; PMCID:
PMC4508500.

5: Wu J, Zhang X, Jia Z, Zhou X, Qi R, Ji H, Sun J, Sun C, Teng Z, Lu G, Chen X.
Combined ¹⁸F-FDG and ¹⁸F-Alfatide II PET May Predict
Luminal B (HER2 Negative) Subtype and Nonluminal Subtype of Invasive Breast
Cancer. Mol Pharm. 2022 Sep 5;19(9):3405-3411. doi:
10.1021/acs.molpharmaceut.2c00547. Epub 2022 Aug 16. PMID: 35972444.

Your view history

Alfatide II new featured